Journal
OPHTHALMOLOGY
Volume 124, Issue 12, Pages 1788-1798Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2017.05.038
Keywords
-
Categories
Funding
- Merck
- Genentech
- Daiichi Sankyo
- Provectus
- Bio Connections LLC
- IMS Health
- Haymarket Media
- Roche
- Pfizer
- BMS
- Fund for Ophthalmic Knowledge
- New York Community Trust
- Research to Prevent Blindness
- Geoffrey Beene Cancer Research Center at Memorial Sloan Kettering Cancer Center
- Cancer Center Grant [P30 CA008748]
Ask authors/readers for more resources
Purpose: To investigate the clinical and morphologic characteristics of serous retinal disturbances in patients taking mitogen-activated protein kinase kinase (MEK) inhibitors. Participants: A total of 313 fluid foci in 50 eyes of 25 patients receiving MEK inhibitors for treatment of their metastatic cancer, who had evidence of serous retinal detachments confirmed by optical coherence tomography (OCT). Design: Single-center, retrospective cohort study. Methods: Clinical examination and OCT were used to evaluate MEK inhibitor-associated subretinal fluid. The morphology, distribution, and location of fluid foci were serially evaluated for each eye. Choroidal thickness was measured at each time point (baseline, fluid accumulation, and fluid resolution). Two independent observers performed all measurements. Statistical analysis was used to correlate interobserver findings and compare choroidal thickness and visual acuity at each time point. Main Outcome Measures: Comparison of OCT characteristics of retinal abnormalities at baseline to fluid accumulation. Results: The majority of patients had fluid foci that were bilateral (92%) and multifocal (77%) and at least 1 focus involving the fovea (83.3%). All fluid foci occurred between the interdigitation zone and an intact retinal pigment epithelium. The 313 fluid foci were classified into 4 morphologies, as follows: 231 (73.8%) dome, 36 (11.5%) caterpillar, 31 (9.9%) wavy, and 15 (4.8%) splitting. Best-corrected visual acuity at fluid resolution was not statistically different from baseline; and no eye lost more than 2 Snellen lines from baseline at the time of fluid accumulation. There was no statistical difference in the choroidal thickness between the different time points (baseline, fluid accumulation, and fluid resolution). A strong positive interobserver correlation was obtained for choroidal thickness measurements (r = 0.97, P < 0.0001) and grading of foci morphology (r = 0.97, P < 0.0001). Conclusion: The subretinal fluid foci associated with MEK inhibitors have unique clinical and morphologic characteristics, which can be distinguished from the findings of central serous chorioretinopathy. In this series, MEK inhibitors did not cause irreversible loss of vision or serious eye damage. (C) 2017 by the American Academy of Ophthalmology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available